US 9,308,256 B2 · Method of treating rheumatoid arthritis with an anti-IL-6R antibody

Abstract

The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.

Claims14

Dependent claims

A method for reducing a symptom of rheumatoid arthritis (RA) in a subject, comprising:

administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof which specifically binds to human interleukin-6-receptor (hIL-6R) with a KD of about 500 pM or less as measured by surface plasmon resonance,
wherein the antibody or antigen-binding fragment comprises a complementarity determining region (CDR) sequence combination of SEQ ID NOs:21/23/25/29/31/33.

Dependencies are inferred from the claim text.

Facts

Application

14/020,573Filed 6 Sep 2013 · division

Priority

2 Jun 2006

Published

US 2014/0255390 A111 Sep 2014

Granted

12 Apr 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 31/4706
Quinolines; Isoquinolines: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 31/655
Medicinal preparations containing organic active ingredients: azo , diazo , azoxy , azido or diazoamino compounds

Family

Application60/810,664Us provisional application · filed 2 Jun 2006

Application60/843,232Us provisional application · filed 8 Sep 2006

Application11/809,482Parent of this division · filed 1 Jun 2007

Application61/181,749Us provisional application · filed 28 May 2009

Application12/501,657Parent of this continuation-in-part · filed 13 Jul 2009

Application61/262,661Us provisional application · filed 19 Nov 2009

Application61/297,302Us provisional application · filed 22 Jan 2010

Application12/780,006Parent of this division · filed 14 May 2010

Application13/286,261Parent of this continuation · filed 1 Nov 2011

Application13/462,938Parent of this division · filed 3 May 2012

US 2014/0255390 A1Pre-grant publication · published 11 Sep 2014

US 8,568,721 B2Parent of this division

US 8,192,741 B2Parent of this continuation

Application13/462,938Parent of this continuation

US 8,080,248 B2Parent of this division

Application13/286,261Parent of this division

US 8,043,617 B2Parent of this continuation-in-part

Application12/780,006Parent of this continuation-in-part

US 7,582,298 B2Parent of this division

Application12/501,657Parent of this division

US 2007/0280945 A1Published application

US 2010/0316627 A1Published application

US 2010/0316636 A1Published application

US 2012/0045440 A1Published application

US 2012/0258098 A1Published application

US 9,308,256 B2This patent

From the US filing history. Foreign family members aren’t listed.

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

Life of this patent

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

Life of this patent

Abstract

Claims14